Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars
LS Rosen, IA Jacobs, RL Burkes - Targeted oncology, 2017 - Springer
Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality
worldwide, with mortality most often attributable to metastatic disease. Bevacizumab, a …
worldwide, with mortality most often attributable to metastatic disease. Bevacizumab, a …
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials
F Petrelli, K Borgonovo, M Cabiddu, M Ghilardi… - Clinical colorectal …, 2013 - Elsevier
Irinotecan and infusional bolus 5-fluorouracil (5-FU)-based chemotherapy (FOLFIRI [5-
fluorouracil, folinic acid, irinotecan])+ bevacizumab (FOLFIRI-B) is 1 of the cornerstones of …
fluorouracil, folinic acid, irinotecan])+ bevacizumab (FOLFIRI-B) is 1 of the cornerstones of …
Molecularly targeted drugs for metastatic colorectal cancer
Y Cheng, H Yang, G Chen, Z Zhang - Drug design, development …, 2013 - Taylor & Francis
The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly
improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a …
improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a …
Real-world cost-effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: population-based retrospective …
Background. Real-world evidence can be a valuable tool when clinical trial data are
incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic …
incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic …
Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal
D Boyers, X Jia, D Jenkinson, G Mowatt - Pharmacoeconomics, 2012 - Springer
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost …
manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost …
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years: a NICE single technology appraisal
J Burch, S Griffin, C McKenna, S Walker, J Paton… - …, 2012 - Springer
Following a licence extension to include those aged 6–11 years, the National Institute for
Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis …
Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis …
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the …
manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the …
[HTML][HTML] Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date
G Zhang, X Zhou, C Lin - International journal of clinical and …, 2015 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide.
Bevacizumab plays an important role in the treatment of metastatic CRC (mCRC). The aim of …
Bevacizumab plays an important role in the treatment of metastatic CRC (mCRC). The aim of …
Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal
B Kearns, M Lloyd Jones, M Stevenson… - Pharmacoeconomics, 2013 - Springer
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of its clinical …
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of its clinical …
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review
F Smieliauskas, CR Chien, C Shen, DM Geynisman… - …, 2014 - Springer
Background Over the last 15 years, a paradigm shift in oncology has led to the approval of
dozens of targeted oral anti-cancer medications (OAMs), which have become the standard …
dozens of targeted oral anti-cancer medications (OAMs), which have become the standard …